TABLE 2.
Clone | Time since X4 (mo)a | Phenotype | Neutralization titer (IC50) at mo since X4a,b
|
|||
---|---|---|---|---|---|---|
−16.2 | −7.5 | 10.5 | 27.0 | |||
171.31.ROF6 | 4.5 | R5 | 125 | 79 | 69 | 87 |
171.33.ROA1 | 10.5 | R5 | 87 | 84 | 81 | 114 |
171.41.ROE2 | 27.0 | R5 | <40 | <40 | <40 | <40 |
171.41.ROC5 | 27.0 | R5 | <40 | <40 | <40 | <40 |
171.31.ROB9 | 4.5 | R5X4 | >1,280 | >1,280 | >1,280 | >1,280 |
171.33.ROA2 | 10.5 | R5X4 | 151 | 768 | 343 | NT |
171.41.D12 | 27.0 | R5X4 | 84 | <40 | 82 | <40 |
171.41.RAF5 | 27.0 | R5X4 | 51 | <40 | <40 | 80 |
Months since X4 variant was detected.
Neutralization was determined by 7-day culture of clonal virus isolates on PBMC in the presence or absence of serial dilutions of serum, followed by analysis of p24 production by ELISA. IC50s were determined by linear regression after subtracting the inhibition obtained using human pooled HIV-1-negative serum.